Read More 48 minute read Uncategorized Stocks That Hit 52-Week Lows On Thursday By Benzinga Insights Today, 6:58 PM During Thursday, 849 stocks hit new 52-week lows.
Read More 44 minute read Uncategorized Stocks That Hit 52-Week Lows On Wednesday By Benzinga Insights Today, 6:58 PM Wednesday's session saw 784 companies set new 52-week lows.
Read More 32 minute read Uncategorized Stocks That Hit 52-Week Lows On Monday By Benzinga Insights Today, 6:58 PM On Monday, 524 stocks hit new 52-week lows.
Read More 10 minute read Uncategorized Stocks That Hit 52-Week Lows On Thursday By Benzinga Insights Today, 6:58 PM During Thursday's morning trading, 152 companies set new 52-week lows.
Read More 25 minute read Uncategorized Stocks That Hit 52-Week Lows On Friday By Benzinga Insights Today, 6:58 PM During Friday's session, 445 companies made new 52-week lows.
Read More 32 minute read Uncategorized Stocks That Hit 52-Week Lows On Thursday By Benzinga Insights Today, 6:58 PM On Thursday, 615 stocks hit new 52-week lows.
Read More 3 minute read Uncategorized Forma Therapeutics Announced Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia at ASH 2021 By Charles Gross Today, 6:58 PM Forma Therapeutics Holdings, Inc.
Read More 4 minute read Uncategorized Forma Therapeutics Early Saturday Announced ‘Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease’ By Benzinga Newsdesk Today, 6:58 PM Updated etavopivat Phase 1 trial results presented in two 2021 ASH Annual Meeting Oral Sessions Etavopivat was well tolerated with a safety profile consistent with underlying sickle cell disease Clinical data in 15
Read More 1 minute read Uncategorized SVB Leerink Maintains Outperform on Forma Therapeutics Hldgs, Lowers Price Target to $40 By Benzinga Newsdesk Today, 6:58 PM SVB Leerink analyst Andrew Berens maintains Forma Therapeutics Hldgs (NASDAQ:FMTX) with a Outperform and lowers the price target from $54 to $40.
Read More 4 minute read Uncategorized Earnings Scheduled For November 12, 2021 By Benzinga Insights Today, 6:58 PM Companies Reporting Before The Bell • Zevia (NYSE:ZVIA) is estimated to report quarterly loss at $0.43 per share on revenue of $34.40 million.